On November 17, 2023, Editas Medicine Inc (NASDAQ: EDIT) opened at $8.88, higher 11.39% from the last session. During the day, the shares moved up to $9.825 and dropped to $8.87 before settling in for the closing price of $8.78. Price fluctuations for EDIT have ranged from $6.08 to $11.93 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 68.84% annually for the last half of the decade. Company’s average yearly earnings per share was noted 24.65% at the time writing. With a float of $81.05 million, this company’s outstanding shares have now reached $81.67 million.
In an organization with 226 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +67.85, operating margin of -1146.26, and the pretax margin is -1118.26.
Editas Medicine Inc (EDIT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.77%, while institutional ownership is 77.41%. The most recent insider transaction that took place on Nov 14, was worth 5,706. In this transaction EVP, CBO AND CTO of this company sold 695 shares at a rate of $8.21, taking the stock ownership to the 74,894 shares. Before that another transaction happened on Nov 07, when Company’s EVP, CBO AND CTO sold 139 for $8.40, making the entire transaction worth $1,168. This insider now owns 75,589 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.55 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.57) by $0.02. This company achieved a net margin of -1118.26 while generating a return on equity of -48.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to -1.50% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 6.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.71, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -2.43 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.83 million. That was better than the volume of 1.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.11%. Additionally, its Average True Range was 0.59.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 98.80%, which indicates a significant increase from 98.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.39% in the past 14 days, which was higher than the 63.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.52, while its 200-day Moving Average is $8.46. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $10.11. Second resistance stands at $10.45. The third major resistance level sits at $11.07. If the price goes on to break the first support level at $9.16, it is likely to go to the next support level at $8.54. Assuming the price breaks the second support level, the third support level stands at $8.20.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 81,674K shares outstanding in the company with a market cap of 798.73 million. Presently, the company’s annual sales total 19,710 K according to its annual income of -220,430 K. Last quarter, the company’s sales amounted to 5,340 K and its income totaled -45,020 K.